On July 24, 2025, at the Annual Meeting, 180 Life Sciences Corp. stockholders approved the Fourth Amendment to the 2022 Incentive Plan, increasing authorized shares from 100 million to 1 billion and adopting the new 2025 Option Incentive Plan with 1 million shares available.